key: cord-0790345-stf3xjgn authors: Bianchi, Francesco Paolo; Germinario, Cinzia Annatea; Migliore, Giovanni; Vimercati, Luigi; Martinelli, Andrea; Lobifaro, Annamaria; Tafuri, Silvio; Stefanizzi, Pasquale title: BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report date: 2021-05-19 journal: J Infect Dis DOI: 10.1093/infdis/jiab262 sha: b094bad7f1c352e304a14793140cb20460c6c570 doc_id: 790345 cord_uid: stf3xjgn In the pre-registration trial, data on the efficacy of the BNT162b2 mRNA vaccine against SARS-CoV-2 infection were not collected. The aim of this study was to evaluate vaccine effectiveness (VE) against documented infection. Bari Policlinico University-Hospital healthcare workers (HCWs) who completed the vaccination schedule were matched with HCWs who had refused vaccination. The VE for documented infection was 61.9% (95%CI=19.2–82.0%) 14–20 days after the first dose, 87.9% (95%CI=51.7–97.0%) 21–27 days after the first dose, and 96.0% (95%CI=82.2–99.1) 7 or more days after the second dose. Unvaccinated HCWs remain a concern even in the context of pandemic emergency. the EU/EEA [3] . Italy ranks first in Europe in the number of COVID-19-related deaths (100,627; fatality rate: 3.2%) and the second per absolute number of cases (n=3,183,605), including 125,803 cases in healthcare workers (HCWs) [4] . Beginning in December 2020, several vaccines aimed at the prevention of SARS-CoV-2 infection and COVID-19 became available in Europe. A mass vaccination campaign was initiated in Italy and other European countries on December 27, 2020. In Italy, the government opted to prioritize the vaccination of HCWs, a decision in line with the recommendations of the United States Center for Disease Control and Prevention (CDC) [5] . By providing critical care to those who are or might be infected by SARS-CoV-2, HCWs are at high risk of exposure to the virus and thus to the development of COVID-19. Furthermore, vaccinating HCWs safeguards healthcare capacity and can prevent those patients hospitalized for reasons other than COVID-19 from becoming infected. The vaccine available to vaccinate HCWs was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty), the first vaccine to be approved by the European Medicines Agency. This vaccine is indicated for individuals 16 years of age and older and is administered in two-doses delivered at least 21 days apart [6, 7] . The pre-licensure trial reported that the vaccine showed 95% efficacy at preventing COVID-19, including severe disease [8] . Aside from transient local and systemic reactions, no safety concerns were identified [8] ; however, the trial did not report any information on the vaccine's efficacy in documented Sars-CoV-2 infection. A c c e p t e d M a n u s c r i p t Recently, a large observational study [9] investigated the vaccines effectiveness (VE) of the BNT162b2 mRNA vaccine on > 1,000,000 Israeli inhabitants (half vaccinated and half unvaccinated) during the period from December 20, 2020, to February 1, 2021. The authors reported that the vaccine prevented symptomatic illness, with a VE of 94% 7 days after the second dose. The same study investigated VE in preventing documented infection. The results showed that 14-20 days after the first dose, the estimated VE for documented infection was 46% (95%CI: 40-51%); 21-27 days after the first dose it was 60% (95%CI: 53-66%) and in the follow-up period starting 7 days after the second dose it was 92% (95%CI 88-95%). It was therefore concluded that the BNT162b2 mRNA vaccine is effective for a wide range of COVID-19-related outcomes, a finding consistent with that of the initial randomized trial. Our observational cohort study was conducted at Bari Policlinico General University-Hospital Two doses of BNT162b2 mRNA vaccine are delivered intramuscularly in the deltoid muscle at least 21 days apart. Vaccination prophylaxis is not mandatory, and the HCW can refuse vaccination. Informed consent is collected at the time of vaccination. All vaccinated HCWs are followed-up for 1 month to assess the development of adverse effects. Policlinico Bari General Hospital has also adopted a specific procedure for the control and prevention of SARS-CoV-2 infection. In order to protect health personnel, the Bari Policlinico Direction made mandatory the use of personal protective equipment (PPE) for each HCW. Furthermore, all asymptomatic HCWs are screened every 14 days for SARS-CoV-2 infection using molecular test on naso-pharyngeal swabs, obtained as recommended by the WHO [11] . Fast-track access to molecular testing is ensured for HCWs with signs and symptoms of COVID-19 (fever, cough, ageusia, etc.). A commercial real-time PCR assay (Allplex2019-nCoV Assay; Seegene, Seoul, Korea) was used to identify the presence of E gene, RdRP gene and N gene of SARS-CoV-2 virus. Data on infection control and prevention are entered into the computerized GIAVA COVID19 platform, as described below. The population in this study comprised HCWs who completed the basal vaccination routine (both doses) between December 27, 2020 and January 31, 2021. They were matched with Bari Policlinico HCWs who during the same period did not receive the vaccine, because they refused vaccination (with the exception of those infected during the first days of the vaccination campaign, corresponding to 37 subjects). HCWs with a documented history of SARS-CoV-2 infection before enrollment were excluded from participation in the study (n=447). The overall vaccination status of HCWs was assessed using the Regional Immunization During the follow-up, there were no serious and/or long-term adverse reactions. The safety of the vaccine is the subject of a report currently in preparation. The VEs determined in our study are slightly higher than those reported by Dagan N et al. [9] , although the value at 7 or more days after the second dose is very similar. However, the sample size of the two studies was very different and our study population consisted solely of HCWs, a group largely excluded by the other study. HCWs are clearly at higher risk of exposure to Sars-CoV-2, which would explain the larger number of infections in our unvaccinated group. Furthermore, since A c c e p t e d M a n u s c r i p t even vaccinated HCWs are periodically screened with a PCR test, to reduce the risk of nosocomial outbreaks, the results for this group are highly reliable and the risk of under-reporting is very low. Keehner J et al. [13] preventing SARS-CoV-2 infections among 3,950 US HCWs, concluding that risk of infection was reduced by 90% two or more weeks after second dose of vaccine [15] . All these evidences match our results. Regarding sample characteristics, it is observed that unvaccinated subjects had a higher age compared to vaccinated ones and that physicians seems to be more compliant to vaccination compared to other professional categories; indeed, many experiences reported in scientific literature [16] showed that older age is a determinant of vaccination hesitancy/refusal, while being a physician is a determinant of vaccination compliance. Further studies are needed to determine the VE of the BNT162b2 mRNA vaccine in different populations and over a longer follow-up period. Thus far, the data are consistent with the absolute effectiveness of the vaccine in the prevention of SARS-CoV-2 infection and in the prevention of COVID-19 disease. These results may influence vaccination willingness among HCWs, as a vaccine that confers disease prevention can be regarded as a form of personal protective equipment. Moreover, a vaccine that prevents infection could dramatically limit circulation of the virus in the hospital setting. Vaccination can therefore be perceived both as a means of self-protection and as an ethical obligation to guarantee the safety of others, especially high-risk hospital patients. Vaccination hesitancy among HCWs has thus far been tolerated, and vaccination has yet to become M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 1 COVID-19 situation update for the EU/EEA, as of week 2 2021 Epidemiology for public health. COVID-19 integrated surveillance data in Italy The Importance of COVID-19 Vaccination for Healthcare Personnel Italian Ministry of Health. Piano vaccini anti Covid-19 jsp?lingua=italiano&id=5452&area=nuovoCoronavirus&menu=vuoto&tab=1. Last accessed on Maarch 3 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting pdf/64801426-f249-72ea-01c1-6fc9fab8552b?t=1615816279358. Last accessed on Use of laboratory methods for SARS diagnosis Data: Managing complex data in outbreaks SARS-CoV-2 Infection after Vaccination in Health Care Workers in California BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers Real-World Study Confirms Protective Benefits of mRNA COVID-19 Compliance with immunization and a biological risk assessment of health care workers as part of an occupational health surveillance program: The experience of a university hospital in southern Italy A c c e p t e d M a n u s c r i p t